Core Points - The annual general meeting of Shenzhen Pumen Technology Co., Ltd. was held on May 7, 2025, with no resolutions being rejected [2][4][5] - All board members, supervisors, and the board secretary attended the meeting, except for one senior management member who was absent due to work reasons [3] - The meeting was conducted in accordance with the Company Law, Securities Law, and the company's articles of association [2][10] Meeting Details - The meeting took place at the company's headquarters in Longhua District, Shenzhen [2] - Voting was conducted through a combination of on-site and online methods [2] - The meeting was chaired by the chairman of the board, Liu Xiancheng [2] Resolutions Passed - Multiple resolutions were approved, including the 2024 annual report, profit distribution plan, and the 2025 financial budget report [4][5][6] - Significant resolutions included the authorization for the board to issue shares to specific targets and the approval of the company's future three-year dividend return plan [6][7] - Resolutions related to related party transactions required certain shareholders to abstain from voting [9] Legal Compliance - The meeting was witnessed by lawyers from Zhonglun Law Firm, confirming that the procedures followed were in compliance with legal requirements [10]

北京市中伦（深圳）律师事务所 关于深圳普门科技股份有限公司 2024 年年度股东大会的 法律意见书 二〇二五年五月 法律意见书 致：深圳普门科技股份有限公司 北京市中伦（深圳）律师事务所（下称"本所"）接受深圳普门科技股份有限公 司（下称"公司"）的委托，指派律师出席公司 2024 年年度股东大会（下称"本次 股东大会"），并根据《中华人民共和国公司法》（下称"《公司法》"）、《上市公司股 东会规则》（下称"《股东会规则》"）等法律、法规和规范性文件及公司现行章程（下 称"《公司章程》"）的有关规定，就本次股东大会的召集和召开程序、召集人资格、 出席和列席会议人员资格、表决程序及表决结果等事宜发表法律意见。 一、本次股东大会的召集和召开程序 北京市中伦（深圳）律师事务所 关于深圳普门科技股份有限公司 2024 年年度股东大会的 为召开本次股东大会，公司董事会于 2025 年 4 月 11 日在《公司章程》规定及 中国证券监督管理委员会指定的信息披露媒体上公告了会议通知。该通知载明了会 议的召开方式、召开时间和召开地点，对会议议题的内容进行了充分披露，说明了 股东有权出席并可委托代理人出席和行使表决权，明确了会 ...

证券代码：688389 证券简称：普门科技 公告编号：2025-040 深圳普门科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 7 日 （二） 股东大会召开的地点：广东省深圳市龙华区求知东路 8 号普门科技总部 大厦 22 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 211 | | --- | --- | | 普通股股东人数 | 211 | | 2、出席会议的股东所持有的表决权数量 | 253,965,289 | | 普通股股东所持有表决权数量 | 253,965,289 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 59.2704 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 59.27 ...

Core Viewpoint - The company, Pumen Technology, experienced a significant decline in its first-quarter performance, with a nearly 50% drop compared to the previous year, raising concerns among investors about its future prospects and the actions of major shareholders [2]. Group 1: Company Performance - As of April 30, 2025, Pumen Technology's stock closed at 12.92 yuan, reflecting a 2.13% increase with a trading volume of 52,300 shares and a transaction value of 67.0357 million yuan [1]. - The company's first-quarter performance was adversely affected by a high revenue base from specific protein business and related luminescent reagent income in the same period last year, attributed to the spread of respiratory diseases in the first quarter of 2024 [2]. Group 2: Shareholder Actions - The company faced scrutiny regarding the complete sell-off of shares by social security funds in the first quarter, leading to speculation about potential undisclosed issues within the company [2]. - The company emphasized that shareholder actions were based on individual investment decisions and not indicative of any internal problems [2]. Group 3: Market Activity - On April 30, 2025, the net inflow of main funds into Pumen Technology was 8.2632 million yuan, accounting for 12.33% of the total transaction value [3][4]. - Retail investors showed a net outflow of 2.6472 million yuan, representing 3.95% of the total transaction value, while speculative funds experienced a net outflow of 5.616 million yuan, or 8.38% of the total [4].

3）格科微 （景林资产管理香港有限公司参与公司业绩说明会） 调研纪要：2024年格科微实现营业收入63.83亿元，同比增长35.90%，净利润1.87亿元，同比增长 287.20%。2025年一季度营收15.24亿元，同比增长18.21%，净利润-0.52亿元。高端手机CIS产品进展顺 利，1,300万以上像素图像传感器收入超15亿元，占比提升至50%。非手机CIS领域推广400万、800万像 素产品，应用于智慧城市、智慧家居等，车载前装图像传感器研发完成，预计2025年推广。临港工厂获 多项认证，满产状态，实现800万、1,300万、5,000万像素产品量产，2024年销售收入22.46亿元。单芯 片架构产品快速导入，5,000万像素产品大量出货，预计下半年毛利率上升。贸易战对公司影响不大， 已做好预案，积极寻求非美化解决方案。公司对高像素单芯片技术成主流充满信心，非手机产品线推进 400万像素及以上产品量产，加大I眼镜和车规级领域投入。 根据市场公开信息及4月29日披露的机构调研信息，知名私募景林资产近期对5家上市公司进行了调研， 相关名单如下： 1）皇马科技 （上海景林资产参与公司特定对象调研） 调研纪 ...

证券代码：688389 证券简称：普门科技 深圳普门科技股份有限公司 2024 年年度股东大会 东代理人的发言。在股东大会进行表决时，股东及股东代理人不再进行发言。 股东及股东代理人违反上述规定，会议主持人有权加以拒绝或制止。 八. 主持人可安排公司董事、监事、高级管理人员回答股东所提问题。对于可能 将泄露公司商业秘密或内幕信息，损害公司、股东共同利益的提问，主持人 或其指定的有关人员有权拒绝回答。 九. 本次股东大会采取现场投票与网络投票相结合的方式表决。出席股东大会的 股东及股东代理人，应当对提交表决的议案发表如下意见之一：同意、反对 或弃权。现场出席的股东请务必在表决票上签署股东名称或姓名。未填、错 填、字迹无法辨认的表决票、未投的表决票均视为投票人放弃表决权利，其 所持股份的表决结果计为"弃权"。请股东及股东代理人按表决票要求填写 表决票，填毕由大会工作人员统一收票。 十. 股东大会对提案进行表决前，将推举两名股东代表参加计票和监票；股东大 会对提案进行表决时，由见证律师、股东代表与监事代表共同负责计票、监 票；本次股东大会采取现场投票和网络投票相结合的方式表决，结合现场投 票和网络投票的表决结果发布 ...

深圳普门科技股份有限公司 证券代码：688389 证券简称：普门科技 公告编号：2025-039 上述注册证的取得仅代表公司相关产品获得国内市场准入资格，产品上市后的实际销售 情况取决于未来市场的推广效果，目前尚无法预测上述产品对公司未来业绩的具体影响。 1 / 2 序号 产品名称 注册 分类 注册证 编号 注册证 有效期至 预期用途 1 血清淀粉样蛋白 A （SAA）测定试剂 盒（免疫散射比浊 法） Ⅱ类 粤械注准 20252400608 2030 年 04 月 23 日 用于体外定量测定人血清、血 浆、全血样本中血清淀粉样蛋白 A（SAA）含量，临床上用于非 特异性炎症的辅助诊断。 一、医疗器械注册证的具体情况 敬请投资者理性投资，注意投资风险。 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司（以下简称"公司"）于近期收到了1个广东省药品监督管理 局颁发的《中华人民共和国医疗器械注册证（体外诊断试剂）》，具体情况如下： 二、对公司的影响 血清淀粉样蛋白 A ...

Summary of the Conference Call for Pumen Technology Company Overview - **Company**: Pumen Technology - **Industry**: Medical Diagnostics and Healthcare Key Points and Arguments Financial Performance - In Q1 2025, the company reported a revenue of 215 million yuan, a year-on-year decrease of 30% [3] - The net profit attributable to shareholders was 53.68 million yuan, down 50% year-on-year [3] - Domestic revenue accounted for 73% of total revenue at 156 million yuan, down 31% year-on-year; international revenue was 59 million yuan, down 24% year-on-year [3] - The decline in domestic revenue was attributed to high base effects from respiratory diseases in Q1 2024, DRGs restrictions, and a 50% price reduction in certain testing projects [3] Revenue Breakdown - In Q1 2025, in vitro diagnostics revenue was 157 million yuan, accounting for 73% of total revenue, down 35% year-on-year [5] - Rehabilitation treatment revenue was 54 million yuan, accounting for 25% of total revenue, down 10% year-on-year, primarily due to a decline in the domestic aesthetic medicine business [5] R&D Investment - R&D expenses increased by 14.7% year-on-year to 43 million yuan, representing 20% of total revenue [6] - The company focused on developing new products and upgrading existing platforms in electrochemistry, liquid chromatography, and immunoturbidimetry [6] Profitability Metrics - Gross margin decreased by 3 percentage points to 65%, while net margin fell by 10 percentage points to 25% [7] - The decline in profitability was mainly due to reduced sales volume and increased R&D investment [7] Market Strategy - The company plans to increase market investment, focusing on high-end hospital promotions and collaborations [9] - The installation of the high-end immunoassay analysis line in high-end hospitals grew by 88% year-on-year [9] Future Outlook - The company expects to achieve double-digit growth for the full year 2025, with a gross margin target of around 65% and a net profit margin target of 25%-30% [4][10] - The company anticipates a recovery in the second quarter, aiming to match last year's performance [10] Product Performance - The high-end glycosylated hemoglobin models saw a significant increase in demand, with the H100 and H100 plus series growing by 277% year-on-year [12] - The company is also focusing on the development of mid-speed immunoassay devices aimed at small and medium hospitals [13] International Market Dynamics - The company has seen growth in the Russian-speaking market, benefiting from the exit of Western brands due to geopolitical tensions [17] - The company is expanding its presence in Kazakhstan and Uzbekistan, with expectations of steady growth in the Russian-speaking region [17] Challenges and Risks - The company faces challenges from DRGs policies affecting inpatient testing packages, which restrict the number of tests that can be ordered simultaneously [24] - The impact of tariffs and international trade uncertainties continues to pose risks to international operations [18][20] Consumer Health Segment - The consumer health segment reported revenue of 8 million yuan in Q1 2025, with a focus on online platforms and potential overseas markets [26] Medical Aesthetics Strategy - The company is preparing for a direct sales strategy targeting reputable medical aesthetic groups while also increasing investment in public dermatology departments [21][22] Conclusion - The company remains optimistic about its long-term growth prospects despite current challenges, emphasizing a commitment to sustainable development and strategic investments [14][30]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688389 证券简称：普门科技 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一) 主要会计数据和财务指标 单位：元 币种：人民币 其他说明： 公司自2024年1月1日起执行财政部发布的《企业会计准则解释第18号》"关于不属于单项履约义务的保 证类质量保证的会计处理"规定以及《企业会计准则应用指南汇编2024》第十二章"股份支付"中明确股 份支付交易按受益对象确认成本费用的内容，公司根据变更后的会计政策追溯调整上年同期相应数据。 (二) 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 对公司将《公开发行证券的公司信 ...

外汇衍生品交易业务管理制度 第一章 总则 第一条 为规范深圳普门科技股份有限公司（以下简称"公司"）的外汇衍生品 交易业务及相关信息披露工作，加强对外汇衍生品交易业务的管理，防范投资风险， 健全和完善公司外汇衍生品交易业务管理机制，确保公司资产安全，根据《中华人 民共和国公司法》《中华人民共和国证券法》《上市公司信息披露管理办法》《上 海证券交易所科创板股票上市规则》《上海证券交易所上市公司自律监管指引第1号 ——规范运作》《上海证券交易所上市公司自律监管指引第5号——交易与关联交易》 等法律法规以及《公司章程》等有关规定，结合公司实际情况，特制订本制度。 第二条 本制度所称外汇衍生品交易业务是指根据公司国际业务的外币收付情 况，在金融机构办理的规避和防范汇率或利率风险的外汇衍生品交易业务，包括远 期结售汇、外汇掉期、外汇期权、利率互换、利率掉期、利率期权等产品或上述产 品的组合。 深圳普门科技股份有限公司 外汇衍生品交易业务管理制度 深圳普门科技股份有限公司 第三条 本制度适用于公司及全资或控股子公司。 第四条 公司外汇衍生品交易业务除遵守国家相关法律、法规及规范行为文件 外，须严格遵守本制度的相关规定，履 ...